Volterrani Maurizio, Halasz Geza, Adamopoulos Stamatis, Agostoni Pier Giuseppe, Butler Javed, Coats Andrew J S, Cohen-Solal Alan, Doehner Wolfram, Filippatos Gerasimos, Jankowska Ewa, Lam Carolyn S P, Lambrinou Ekaterini, Lund Lars H, Rosano Giuseppe, Metra Marco, Paolillo Stefania, Perrone Filardi Pasquale, Rakisheva Amina, Savarese Gianluigi, Seferovic Petar, Tocchetti Carlo Gabriele, Piepoli Massimo
IRCCS San Raffaele Roma, 00166 Rome, Italy.
San Raffaele Open University in Rome, Italy.
Eur J Prev Cardiol. 2025 Aug 25;32(11):912-925. doi: 10.1093/eurjpc/zwad400.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity. Usual endpoints of large-scale trials in chronic HF have mostly been defined to evaluate treatments regarding hospitalizations and mortality, but more recently, patients' priorities and needs expressed with QoL are gaining more awareness and are being more extensively evaluated. This scientific statement aims at discussing the importance of QoL in HF, summarizing the most largely adopted questionnaires in HF care, and providing an overview on their application in trials and the potential for their transition to clinical practice. Finally, by discussing the reasons limiting their application in daily clinical routine and the strategies that may promote their implementation, this statement aims at fostering the systematic integration of the patient's standpoint in HF care.
